186 related articles for article (PubMed ID: 9893764)
1. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD.
Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H
Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764
[TBL] [Abstract][Full Text] [Related]
2. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
4. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure.
Kinugawa T; Kato M; Yamamoto K; Hisatome I; Nohara R
Int Heart J; 2012; 53(3):182-6. PubMed ID: 22790687
[TBL] [Abstract][Full Text] [Related]
6. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
[TBL] [Abstract][Full Text] [Related]
7. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
8. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy.
Zen K; Irie H; Doue T; Takamiya M; Yamano T; Sawada T; Azuma A; Matsubara H
Int Heart J; 2005 Mar; 46(2):231-44. PubMed ID: 15876807
[TBL] [Abstract][Full Text] [Related]
9. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C.
Toyoda M; Kakizaki S; Horiguchi N; Sato K; Takayama H; Takagi H; Nagamine T; Mori M
Liver; 2000 Jul; 20(4):305-11. PubMed ID: 10959809
[TBL] [Abstract][Full Text] [Related]
10. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
[TBL] [Abstract][Full Text] [Related]
11. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
Adamopoulos S; Parissis J; Karatzas D; Kroupis C; Georgiadis M; Karavolias G; Paraskevaidis J; Koniavitou K; Coats AJ; Kremastinos DT
J Am Coll Cardiol; 2002 Feb; 39(4):653-63. PubMed ID: 11849865
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of apoptosis in scorpion envenomed children: its reflection on their outcome.
Meki AR; Hasan HA; El-Deen ZM; Bakkar S
Toxicon; 2003 Sep; 42(3):229-37. PubMed ID: 14559073
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of soluble Fas ligand in cachexic patients with COPD are higher than those in non-cachexic patients with COPD.
Takabatake N; Arao T; Sata M; Inoue S; Abe S; Shibata Y; Kubota I
Intern Med; 2005 Nov; 44(11):1137-43. PubMed ID: 16357450
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases.
Kamihira S; Yamada Y; Hiragata Y; Yamaguchi T; Izumikawa K; Matsuo Y; Sugahara K; Tsuruta K; Atogami S; Tsukasaki K; Maeda T; Tomonaga M
Intern Med; 1997 Mar; 36(3):166-70. PubMed ID: 9144006
[TBL] [Abstract][Full Text] [Related]
15. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
16. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans.
Lenzlinger PM; Marx A; Trentz O; Kossmann T; Morganti-Kossmann MC
J Neuroimmunol; 2002 Jan; 122(1-2):167-74. PubMed ID: 11777556
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction.
Ohtsuka T; Hamada M; Sasaki O; Suzuki M; Hara Y; Shigematsu Y; Ohtani T; Honda T; Hiwada K
Coron Artery Dis; 1999 Jun; 10(4):221-5. PubMed ID: 10376200
[TBL] [Abstract][Full Text] [Related]
18. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
19. Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.
Kawahito K; Misawa Y; Fuse K
Artif Organs; 2000 Aug; 24(8):628-31. PubMed ID: 10971250
[TBL] [Abstract][Full Text] [Related]
20. Plasma sFas and sFas ligand levels in patients with thrombotic thrombocytopenic purpura and in those with disseminated intravascular coagulation.
Hori Y; Wada H; Mori Y; Shimura M; Hiyoyama K; Nakasaki T; Nishii K; Tamaki S; Nishikawa M; Deguchi K; Minami N; Shiku H
Am J Hematol; 1999 May; 61(1):21-5. PubMed ID: 10331507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
